Literature DB >> 22285761

Crystal structure of the urokinase receptor in a ligand-free form.

Xiang Xu1, Henrik Gårdsvoll, Cai Yuan, Lin Lin, Michael Ploug, Mingdong Huang.   

Abstract

The urokinase receptor urokinase-type plasminogen activator receptor (uPAR) is a surface receptor capable of not only focalizing urokinase-type plasminogen activator (uPA)-mediated fibrinolysis to the pericellular micro-environment but also promoting cell migration and chemotaxis. Consistent with this multifunctional role, uPAR binds several extracellular ligands, including uPA and vitronectin. Structural studies suggest that uPAR possesses structural flexibility. It is, however, not clear whether this flexibility is an inherent property of the uPAR structure per se or whether it is induced upon ligand binding. The crystal structure of human uPAR in its ligand-free state would clarify this issue, but such information remains unfortunately elusive. We now report the crystal structures of a stabilized, human uPAR (H47C/N259C) in its ligand-free form to 2.4 Å and in complex with amino-terminal fragment (ATF) to 3.2 Å. The structure of uPAR(H47C/N259C) in complex with ATF resembles the wild-type uPAR·ATF complex, demonstrating that these mutations do not perturb the uPA binding properties of uPAR. The present structure of uPAR(H47C/N259C) provides the first structural definition of uPAR in its ligand-free form, which represents one of the biologically active conformations of uPAR as defined by extensive biochemical studies. The domain boundary between uPAR DI-DII domains is more flexible than the DII-DIII domain boundary. Two important structural features are highlighted by the present uPAR structure. First, the DI-DIII domain boundary may face the cell membrane. Second, loop 130-140 of uPAR plays a dynamic role during ligand loading/unloading. Together, these studies provide new insights into uPAR structure-function relationships, emphasizing the importance of the inter-domain dynamics of this modular receptor. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285761     DOI: 10.1016/j.jmb.2011.12.058

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  23 in total

1.  Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Authors:  Julie M Leth; Haydyn D T Mertens; Katrine Zinck Leth-Espensen; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2019-03-20       Impact factor: 5.157

2.  Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.

Authors:  Degang Liu; David Xu; Min Liu; William Eric Knabe; Cai Yuan; Donghui Zhou; Mingdong Huang; Samy O Meroueh
Journal:  Biochemistry       Date:  2017-03-17       Impact factor: 3.162

3.  Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Authors:  Timmy Mani; Degang Liu; Donghui Zhou; Liwei Li; William Eric Knabe; Fang Wang; Kyungsoo Oh; Samy O Meroueh
Journal:  ChemMedChem       Date:  2013-10-02       Impact factor: 3.466

4.  Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain.

Authors:  Wanee Plengpanich; Stephen G Young; Weerapan Khovidhunkit; André Bensadoun; Hirankorn Karnman; Michael Ploug; Henrik Gårdsvoll; Calvin S Leung; Oludotun Adeyo; Mikael Larsson; Suwanna Muanpetch; Supannika Charoen; Loren G Fong; Sathit Niramitmahapanya; Anne P Beigneux
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

Review 5.  Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  Biochem J       Date:  2016-08-01       Impact factor: 3.857

6.  Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.

Authors:  Anthony F Rullo; Kelly J Fitzgerald; Viswanathan Muthusamy; Min Liu; Cai Yuan; Mingdong Huang; Minsup Kim; Art E Cho; David A Spiegel
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

7.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

8.  GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.

Authors:  Anne P Beigneux; Loren G Fong; André Bensadoun; Brandon S J Davies; Monika Oberer; Henrik Gårdsvoll; Michael Ploug; Stephen G Young
Journal:  Circ Res       Date:  2014-11-11       Impact factor: 17.367

9.  A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Haydyn D T Mertens; Magnus Kjaergaard; Simon Mysling; Henrik Gårdsvoll; Thomas J D Jørgensen; Dmitri I Svergun; Michael Ploug
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

10.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.